Michał Bohdan

Dr. Michał Bohdan

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MBMichał Bohdan
Michał Bohdan
AKAnna Kowalczys
Anna Kowalczys
AMAgnieszka Mickiewicz
Agnieszka Mickiewicz
MGMarcin Gruchala
Marcin Gruchala
ELEwa Lewicka
Ewa Lewicka
Cardiovascular (CV) diseases and cancer are the leading causes of death in Europe and the United States. Both diseases have extensive overlap and share common risk factors, symptoms, and outcomes. As the number of patients with both cancer and CV diseases continues to rise, the field of cardio-oncology is gaining increased attention. A frequent problem during anti-cancer treatment is cardiotoxicity caused by the side-effects of chemo-, immuno-, targeted, and radiation therapies. This problem may manifest as acute coronary syndrome, myocarditis, arrhythmias, or heart failure. Modern cardio-oncology spans many different research areas. While some researchers focus on treating patients that have already developed cardiotoxicity, others aim to identify new methods for preventing cardiotoxicity before, during, and after anti-cancer therapy. Both groups share the common understanding that regular monitoring of cancer patients is the basis for optimal medical treatment. Optimal treatment can only be achieved through close cooperation between cardiologists and oncologists. This review summarizes the current views on cardio-oncology and discusses the cardiotoxicities associated with commonly used chemotherapeutics.

Verified
Journal Article
Open access
PDF file
DPDorota Purzycka-Bohdan
Dorota Purzycka-Bohdan
ACAnna Helena Czarnecka
Anna Helena Czarnecka
MBMichał Bohdan
Michał Bohdan
Aneta Szczerkowska-DoboszAneta Szczerkowska-Dobosz
Aneta Szczerkowska-Dobosz
MAMarta Sobalska-Kwapis (1st author)
Marta Sobalska-Kwapis (1st author)
Roman J. NowickiRoman J. Nowicki
Roman J. Nowicki
Cardiovascular risk factors are one of the most common comorbidities in psoriasis. A higher prevalence of hypertension, insulin resistance and type 2 diabetes, dyslipidemia, obesity, metabolic syndrome, depression, as well as cardiovascular disease was confirmed in psoriatic patients in comparison to the general population. Data suggest that psoriasis and systemic inflammatory disorders may originate from the pleiotropic interactions with many genetic pathways. In this review, the authors present the current state of knowledge on the potential genetic links between psoriasis and cardiovascular risk factors. The understanding of the processes linking psoriasis with cardiovascular risk factors can lead to improvement of psoriasis management in the future.

1 October 2014 in Transplantation Proceedings
Verified
Journal Article
Closed access
Justyna GołębiewskaJustyna Gołębiewska
Justyna Gołębiewska
ISI. Stopczyńska
I. Stopczyńska
Alicja Dębska-ŚlizieńAlicja Dębska-Ślizień
Alicja Dębska-Ślizień
MBMichał Bohdan
Michał Bohdan
MGMarcin Gruchala
Marcin Gruchala
BRB. Rutkowski
B. Rutkowski

25 February 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
ACAnna Helena Czarnecka
Anna Helena Czarnecka
DPDorota Purzycka-Bohdan
Dorota Purzycka-Bohdan
MZMonika Zablotna
Monika Zablotna
Roman J. NowickiRoman J. Nowicki
Roman J. Nowicki
KRKrzysztof Rębała
Krzysztof Rębała
Aneta Szczerkowska-DoboszAneta Szczerkowska-Dobosz
Aneta Szczerkowska-Dobosz
This study aimed to comprehensively analyze the problem of overweight and obesity among psoriatic patients by investigating the influence of body mass composition, anhedonia and depression, environmental factors and FTO gene polymorphisms. Methods: The study enrolled 30 overweight or obese adult patients with chronic plaque psoriasis and 30 overweight or obese volunteers (northern Poland region, Caucasian population). Mood disorders, body mass composition by using bioelectrical impedance analysis (BIA) and FTO gene polymorphisms (rs9939609, rs1558902) by tetra-primer amplification refractory mutation system PCR (T-ARMS-PCR) were assessed. Results: Results revealed significantly higher visceral adipose tissue levels in psoriatic patients (5.23 ± 2.29 [L] vs. 3.41 ± 1.86 [L]), p = 0.001), especially among men, along with elevated rates of moderate and severe depression (26.67% vs. 6.67% and 13.33% vs. 3.33%, p = 0.048 respectively). Additionally, FTO gene polymorphisms correlated with waist–hip ratio differences in both groups. Conclusions: The study highlights the importance of evaluating body composition beyond body mass index, recognizing its influence on psoriasis and associated conditions like depression. The FTO gene may serve as a potential genetic link between psoriasis and obesity, warranting further research for validation. Adiposity emerges as a key and modifiable risk factor, underscoring the clinical implications of body composition complexities in psoriasis management.

26 February 2023 in Genes
Verified
Journal Article
Open access
PDF file
ACAnna Helena Czarnecka
Anna Helena Czarnecka
DPDorota Purzycka-Bohdan
Dorota Purzycka-Bohdan
MZMonika Zablotna
Monika Zablotna
MBMichał Bohdan
Michał Bohdan
Roman J. NowickiRoman J. Nowicki
Roman J. Nowicki
Aneta Szczerkowska-DoboszAneta Szczerkowska-Dobosz
Aneta Szczerkowska-Dobosz
Psoriasis comorbidities may emerge from pleiotropic mechanisms, including common proinflammatory pathways, cellular mediators or genetic predisposition. Obesity is considered to be an independent risk factor of psoriasis, which may influence the severity of the disease and its early onset, decrease patients’ quality of life, alter response to psoriasis therapies and affect morbidity by reduced life expectancy due to cardiovascular events. Although novel approaches, including genetic techniques, have provided a wide range of new research, there are still scarce studies elaborating on the common genetic background of psoriasis and obesity. The aim of this study was to present and evaluate a possible common genetic background of psoriasis and concomitant increased body mass based on the review of the available literature.

4 July 2022 in Cardiology Journal
Verified
Journal Article
Open access
PDF file
MBMichał Bohdan
Michał Bohdan
ISIwona Stopczyńska
Iwona Stopczyńska
PWPiotr Wiśniewski
Piotr Wiśniewski
JMJoanna Moryś
Joanna Moryś
PNPiotr Niedoszytko
Piotr Niedoszytko
MGMarcin Gruchała
Marcin Gruchała
Background: Trimetazidine (TMZ) modulates cardiac metabolism, but its use in heart failure remains controversial. The aim of the study was to evaluate the effects of TMZ on exercise capacity, left ventricular ejection fraction (LVEF), mortality, and quality of life in stable patients with heart failure with reduced left ventricular ejection fraction (HFrEF). Methods: Forty-five patients with stable advanced HFrEF treated with optimal medical therapy were randomized in a prospective, single-center, open-label, cross-over study of trimetazidine (35 mg b.i.d.) on top of standard medical therapy or standard pharmacotherapy for two periods of 30 days and one period of 6 months. Initially and at the end of each period all patients underwent the following: exercise testing, six-minute walk test (6MWT), two-dimensional-echocardiography, and quality of life assessment. Results: The mean age of patients was 58.2 ± 10.6 years. Etiology of HFrEF was ischemic in 66.6% of patients. After 6 months no significant changes were observed in either group with regards to peak VO2 uptake, 6MWT, LVEF, or quality of life. TMZ had no effect on mortality or cardiovascular events. Conclusions: The additional use of TMZ on top of standard medical therapy in stable advanced HFrEF patients was not associated with significant changes in mortality, exercise capacity, LVEF, or quality of life. Background: Trimetazidine (TMZ) modulates cardiac metabolism, but its use in heart failure remains controversial. The aim of the study was to evaluate the effects of TMZ on exercise capacity, left ventricular ejection fraction (LVEF), mortality, and quality of life in stable patients with heart failure with reduced left ventricular ejection fraction (HFrEF). Methods: Forty-five patients with stable advanced HFrEF treated with optimal medical therapy were randomized in a prospective, single-center, open-label, cross-over study of trimetazidine (35 mg b.i.d.) on top of standard medical therapy or standard pharmacotherapy for two periods of 30 days and one period of 6 months. Initially and at the end of each period all patients underwent the following: exercise testing, six-minute walk test (6MWT), two-dimensional-echocardiography, and quality of life assessment. Results: The mean age of patients was 58.2 ± 10.6 years. Etiology of HFrEF was ischemic in 66.6% of patients. After 6 months no significant changes were observed in either group with regards to peak VO2 uptake, 6MWT, LVEF, or quality of life. TMZ had no effect on mortality or cardiovascular events. Conclusions: The additional use of TMZ on top of standard medical therapy in stable advanced HFrEF patients was not associated with significant changes in mortality, exercise capacity, LVEF, or quality of life.